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It has been accepted since the 1990s that palliative chemotherapy can significantly prolong the survival of patients with advanced gastric carcinoma, compared to supportive care alone \[[@B1],[@B2]\]. However, there is controversy over the benefit of salvage therapy past second-line due to the lack of evidence. Recently, there has been renewed interest in salvage chemotherapy after first- and second-line treatments have failed because of the prolonged survival time and relatively low toxicity of agents.

Many clinicians consider second-line chemotherapy after failure of first-line chemotherapy for patients with advanced gastric carcinoma \[[@B3]\]. Phase II trials and retrospective analyses have provided evidence that second-line is effective \[[@B4]\]. Recently, randomized phase III trials have strongly indicated that second line or further chemotherapy is more advantageous than supportive care ([Table 1](#T1){ref-type="table"}). A German trial found that irinotecan monotherapy improved overall survival compared to best supportive care \[[@B5]\]. A Korean trial found that irinotecan or docetaxel monotherapy prolonged overall survival compared to best supportive care and there was no difference in the treatment effect of docetaxel and irinotecan (*p* = 0.116) \[[@B6]\]. In the 2013 the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, it was reported that docetaxel \[[@B7]\] and ramucirumab \[[@B8]\] demonstrated clinical benefit over supportive care in two phase III trials. Both agents significantly prolonged overall survival ([Table 1](#T1){ref-type="table"}). There is ample evidence to support the use of second line treatment in advanced gastric cancer. However, the issue of which regimen is a standard second-line treatment has not been clarified.

Little information concerning the survival advantage of third-line chemotherapy is extant. In a Korean phase III trial, the survival benefit in the chemotherapy arm was preserved in the further chemotherapy group (hazard ratio, 0.812; 95% confidence interval \[CI\], 0.450 to 1.464) ([Table 1](#T1){ref-type="table"}). Several retrospective studies presented the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment \[[@B4]\]. The survival prolongation by second- and third-line salvage chemotherapy indicates its feasibility in selected patients.

After failure of first-line chemotherapy based on platinum and fluoropyrimidine, irinotecan, or taxane-based regimens have benefited survival and led to the same clinical outcome as salvage chemotherapy in advanced gastric cancer patients \[[@B4],[@B6]\]. Based on the lack of cross-resistance between irinotecan and taxane, both regimens are plausible salvage treatment options. Additionally, it is necessary to select patients for salvage chemotherapy based on survival predictors including performance status, chemotherapy-free interval, response duration, metastatic pattern, tumor burden, and serum carcinoembryonic antigen level \[[@B4],[@B6]\].

Lee and colleagues \[[@B9]\] evaluated the efficacy and toxicity of docetaxel monotherapy, 75 mg/m^2^ on day 1 every 3 weeks, in advanced gastric cancer patients who did not respond to oxaliplatin with leucovorin and 5-fluorouracil (m-FOLFOX-4), or to irinotecan with leucovorin and 5-fluorouracil (m-FOLFIRI). This retrospective study included thirty three patients and reported an overall response of 15%, time to progression of 2.1 months (95% CI, 1.63 to 2.58), and an overall survival time of 4.7 months (95% CI, 3.20 to 6.20). The results are comparable to previous reports of the efficacy of third-line treatment. This study provides important evidence that docetaxel is a feasible third-line therapy regimen after m-FOLFIRI and m-FOLFOX-4 regimens. A randomized prospective trial could further support this conclusion.

Trastuzumab, a molecular target agent, was approved for HER2 amplified gastric cancer patients, and other anti-HER2 agents-including lapatinib-have been evaluated as first- or second-line treatments. Furthermore, studies have been performed to elucidate biomarkers of chemotherapeutic agents and to investigate molecular biological features, including genetic and epigenetic profiles \[[@B10]\]. On the basis of those outcomes, randomized trials of target agents, and molecular biologic markers would facilitate treatment tailored to the individual patient.
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BSC, best supportive care; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
